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Background: To describe a simple quantitative immunoﬂuorescence assay (IFA) for the detection of speciﬁc Stenotrophomonas maltophilia
antibodies in serum of CF patients.
Methods: A total of 100 sera (64 CF patients and 36 healthy subjects) were collected over a period of 2 years at the University Hospital Essen,
Germany. Sputum culture status classiﬁed CF patients into groups. Serologic response was determined after Pseudomonas aeruginosa absorption
by indirect IFA to Sm whole cell.
Results: CF patients with “chronic S. maltophilia” showed signiﬁcantly higher S. maltophilia antibody levels compared with healthy individuals
(P b 0.0001) and CF patients with “intermittent” (P = 0.0315) or “never S. maltophilia/P. aeruginosa” (P = 0.0002). A discriminant cut-off value
of N1:120 titre was established to differentiate “CF chronic S. maltophilia” from the other groups. For “CF chronic S. maltophilia”, the IFA showed
sensitivity and speciﬁcity values of 70.7% and 84.7%, respectively.
Conclusion: Our data demonstrated that quantitative IFA is a simple serological assay for the detection of speciﬁc S. maltophilia antibodies, which
could be useful as a diagnostic tool for monitoring immune response of CF patients to S. maltophilia.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: S. maltophilia; Cystic ﬁbrosis; Immune response1. Introduction
Data regarding the clinical consequences and importance of
Stenotrophomonas maltophilia colonisation in cystic fibrosis (CF)
airways are still debated upon. However, it has been recently
demonstrated that chronic S. maltophilia infection is an indepen-
dent risk factor for pulmonary exacerbation [1]. Therefore,
infection markers for S. maltophilia, such as antibodies, may be
helpful to determine the state by colonisation/infection of this
bacterium in CF patients [1,2].
Different studies for Pseudomonas aeruginosa have indicated
that serologic testing is not only a good tool for monitoring⁎ Corresponding author at: Institute of Medical Microbiology, University Hospital
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antibodies are related to a risk factor for developing chronic
infection [2–4]. Since chronic exposure to a pathogen normally
leads to a specific immune response, we developed a quantitative
immunofluorescence assay (IFA) for the detection of specific
S. maltophilia antibodies in serum of CF patients. Further, we
correlated the S. maltophilia antibody titres with the categories of
S. maltophilia and P. aeruginosa colonisation in different groups
of CF patients. Healthy subjects were included as a control group.2. Methods
Serum samples from randomly selected CF patients and healthy
subjects were collected between January 2009 andDecember 2011
at the University Hospital Essen, Germany. The serum collectionby Elsevier B.V. All rights reserved.
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were classified based on their sputum culture status within the
study period as previously described [1]: chronic, two or more
positive sputum cultures for S. maltophilia in a given year;
intermittent, one positive culture for S. maltophilia in a given
year or previous positive culture; and never S. maltophilia,
absence of positive culture for S. maltophilia. To investigate
potential cross-reactivity of P. aeruginosa antibodies, we had
additional groups composed of: “CF patients never S. maltophilia/
P. aeruginosa” and “CF patients never S. maltophilia but chronic
P. aeruginosa”. Serologic response was measured by indirect
IFA using S. maltophilia (ATCC13637) whole cell as antigen,
which was visualised by Fluoline H IgG fluorescence (Ref 75
603, bioMérieux, Nottingham, UK). Absorption of antibodies was
performed by adding P. aeruginosa (ATCC 27853) to the serum.
We observed that without the absorption procedure, S. maltophilia
antibody titres were about 1-fold higher. Treated P. aeruginosa
cells were incubated with formalin (final concentration at 1%) for
48 h at room temperature. After centrifugation the supernatant was
used for testing. Results were expressed as a quantitative antibody
level (titre). An unpaired non-parametric Mann Whitney test was
used to assess if there were significant differences in the antibody
titres between the groups. Optical cut-off titres were defined by
receiver operating characteristic (ROC) curve analyses, by finding
the highest sensitivity and specificity points [5]. Sensitivity and
specificity values were calculated at 95% confidence intervals
(CI) using the Prism 5.0 software package (Graph Pad Software,
San Diego, CA, USA).
3. Results
A total of 100 sera samples from 64 CF patients and 36
healthy subjects were obtained and investigated for the presence
of S. maltophilia antibodies. Out of the 64 CF patients, 28
(43.75%) had “chronic S. maltophilia” colonisation, 10 (15.7%)
had “intermittent S. maltophilia” colonisation and 11 (17.2%) had
“never S. maltophilia/P. aeruginosa” isolated from the respira-
tory tract. In addition, 15 (23.4%) CF patients were chronically
colonised with P. aeruginosa but never with S. maltophilia.Table 1
Demographic and clinical data regarding healthy subjects and CF patient groups.
Characteristic Healthy
(n = 36)
Never Sm/Pa
(n = 11)
Sm antibody titre (geometric mean) 0.91 7.3
Age, mean (SD) 31.9 (±9.7) 14.0 (±7.9)
Sex (male) 18 (50%) 9 (81.9%)
Mutation dF580/dF580 – 18.1%
Pancreatic insufficiency – 90.9%
CFDR – 0.0%
BMI (range) – 18.1 (14.1–22.3)
FEV1 mean range – 84.7 (35–111)
Pseudomonas aeruginosa positive – 0.0%
Burkholderia cepacia positive – 0.0%
Aspergillus positive – 18.1%
Lung transplant – 0.0%
Definitions of abbreviations: Sm = Stenotrophomonas maltophilia; BMI = body m
volume in 1 s.Patient baseline characteristics are summarised in Table 1.
When the relationship between antibody levels and FEV1 was
investigated, we observed a significant inverse correlation
between the mean of S. maltophilia antibody titres and FEV1
percent predicted (R square = 0.2106; P = 0.0013). This fact
indicated that CF patients with high antibody titres tended to have
a higher FEV1 value. Due to the limited number of patients we
did not perform multivariate regression analysis to address the
relationships between S. maltophilia antibody titre and markers
of clinical outcome.
The levels of Sm antibodies differed substantially between
the three groups of CF patients, except for between CF patient
groups “never S. maltophilia/P. aeruginosa” and “intermittent
S. maltophilia” (P = 0.2688) (Fig. 1). CF patients with “chronic
S. maltophilia” showed significantly higher S. maltophilia
antibody levels compared with healthy individuals (P b
0.0001), CF patients with “intermittent” (P = 0.0315) or “never
S. maltophilia/P. aeruginosa” (P = 0.0002). No significant
difference was found between antibody titres of the CF groups
“never S. maltophilia/P. aeruginosa” and “never S. maltophilia but
chronicP. aeruginosa” (P = 0.1898), indicating no cross-reactivity
of S. maltophilia antibodies with P. aeruginosa.
The ROC curve analysis for identifying CF S. maltophilia
chronically colonised patients is shown in Fig. 2. The area under
the receiver operating characteristic curve (AUC), which is
recognized as a measurement of the discriminatory power of the
diagnostic test, was 0.88 (95% CI: 0.59–0.91). The best cut-off
value of N1:120 titre provided both the highest sensitivity and
specificity to distinguish CF “never S. maltophilia/P. aeruginosa”
and CF “chronic S. maltophilia”. On this basis [6], sensitivity,
specificity, positive predictive value (PPV) and negative predictive
values (NPV)were 78.5%, 81.8%, 70.7% and 84.7%, respectively.
4. Discussion
In this study, we developed a simple and practical serological
quantitative IFA for the specific detection of S. maltophilia
antibody levels in CF patients and correlated the S. maltophilia
titres with colonisation status. We demonstrated that CF patientsIntermittent Sm
(n = 10)
Chronic Sm
(n = 28)
Chronic Pa never Sm
(n = 15)
22.6 320.1 30.5
20.0 (±10.1) 21.2 (±8.9) 26.0 (±7.2)
5 (50.0%) 13 (46.0%) 6 (40.0%)
60.0% 50.0% 73.3%
100.0% 75.0% 93.3%
20.0% 10.7% 33.3%
19.3 (15.1–23.4) 18.0 (14.5–23.8) 19.8 (16.2–30.4)
61.7 (40–94) 55.7 (28–108) 56.4 (16–116)
90.0% 50.0% 100.0%
0.0% 0.0% 0.0%
80.0% 53.5% 86.7%
0.0% 0.0% 6.7%
ass index; CFDR = cystic fibrosis-related diabetes; FEV1 = forced expiratory
Fig. 1. A) Antibody levels of S. maltophilia (Sm) whole cell in serum samples from healthy subjects (healthy), CF patients with chronic (CF chronic Sm), intermittent
(CF intermittent Sm), and never Sm without P. aeruginosa (CF never Sm/Pa). Antibody levels are reported as titres. P values b 0.0005 by non-parametric test were
considered significantly different. B) Comparison of antibody titre between CF “never Sm/Pa” and CF never Sm but chronic Pa. Antibody titres did not differed
between the groups (P = 0.1898).
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antibody titre compared to healthy individuals, “CF never
S. maltophilia/P. aeruginosa” (P = 0.0002) and “CF intermittent
S. maltophilia” (P = 0.0315), respectively.
One of the technical challenges was to identify a sero-
logical response consistently expressed by the majority of CF
S. maltophilia chronic sera, avoiding cross-reactivity with
P. aeruginosa. For that reason, Pa absorption was performed
with all samples, to minimise any residual antibodies that might
be present in sera from CF patient groups. In fact, we did not
find any differences in IFA titres between Pa positive and Pa
negative patients. We selected S. maltophilia as a whole-cell
antigen to conduct the IFA, since some epitopes which can beFig. 2. Receiver operating curve (ROC) for IFA detecting serum antibodies against
Sm whole cell. ROC data (area = 0.8815; std. error = 0.052; P = 0.0002) of CF
patients never colonised S. maltophilia/P. aeruginosa (Sm/Pa) versus CF patients
with chronic S. maltophilia (Sm).buried within the outer membrane and might not be available
on the bacterial surface [7] antibodies that are able to bind to the
intact bacterium are more likely to be protective.
We showed that the immune response to whole-cell Sm in
CF patients who were chronically infected with S. maltophilia
was significantly higher than in both healthy subjects and CF
“never Sm/Pa”, suggesting that these patients were not simply
colonised but “persistently colonised”. This fact was also
highlighted by the observation of lower FEV1 in these patients.
At satisfactory specificity (true negative) and sensitivity (true
positive) values of 81.8% and 78.5% respectively, ROC curve
data allowed us to establish a discriminant cut-off value of
N1:120 with a high degree of confidence. However, because
sensitivity and specificity are not defined by the prevalence of
S. maltophilia colonisation in the investigated CF population,
PPV and NPV values were calculated. The NPV value was
84.7%, suggesting that only 15.3% of the CF patients tested
positive for S. maltophilia antibodies but were not colonised by
this pathogen.
Antibody testing to detect P. aeruginosa chronic infection in
CF patients has been already investigated in the past. High
values for sensitivity and specificity of serum antibodies for this
pathogen were detected by different studies [3,4,8,9]. Similarly
for S. maltophilia, a Danish research group noticed an increased
level of precipitating S. maltophilia antibodies in 21 chronically
infected CF patients during the study period [2]. Likewise, a
Canadian group observed that patients chronically infected with
S. maltophilia had significant higher mean antibody levels of
S. maltophilia flagellin (P b 0.001) and whole cell (P = 0.0004)
in comparison with CF “intermittent” or “never S. maltophilia”,
using ELISA technique [1]. In fact, our findings observed in a
German cohort were consistent with the data already shown for
P. aeruginosa, and also with the recent results obtained for
654 P.G. Vidigal et al. / Journal of Cystic Fibrosis 12 (2013) 651–654S. maltophilia. In our case, we performed IFA with whole cell
S. maltophilia and we were able to define a discriminant cut-off.
In addition, to better characterise the immune response to S.
maltophilia, we have also included healthy individuals as a control
group. Our future perspectives will focus on addressing additional
issues, such as: the relevance of increased S. maltophilia antibody
levels over time; the significance of seroconversion in childhood;
and finally, whether antibody titre is reduced after specific therapy
against S. maltophilia.
In conclusion, our results showed that a quantitative IFA is a
simple serological assay for the detection of specific S. maltophilia
antibodies, which from a clinical perspective, could be used as a
diagnostic tool for monitoring CF patients' S. maltophilia status.Funding
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